EBOS Group Limited

Equities

EBO

NZEBOE0001S6

Pharmaceuticals

End-of-day quote New Zealand S.E. 06:00:00 2024-06-19 pm EDT 5-day change 1st Jan Change
32.66 NZD +1.33% Intraday chart for EBOS Group Limited +0.80% -8.00%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
New Zealand shares fall as hopes of early Fed rate cut fade; Australia closed RE
Jarden Securities Upgrades Ebos Group to Overweight from Neutral, Price Target is NZ$38.00 MT
New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO MT
Ebos Group Appoints New CFO MT
EBOS Group Limited Announces Chief Financial Officer Changes CI
Evans & Partners Starts Ebos Group at Positive, Price Target is NZ$40.94 MT
Ebos Group Declares DRP Strike Price for Interim Dividend MT
Morgan Stanley Adjusts EBOS Group’s Price Target to AU$37 From AU$38, Keeps at Overweight MT
Morgan Stanley Adjusts EBOS’ Price Target to NZ$39.20 From NZ$41.05, Keeps at Overweight MT
EBOS Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
EBOS Group Limited to Seek M&A CI
Transcript : EBOS Group Limited, H1 2024 Earnings Call, Feb 21, 2024
EBOS Posts 7% Rise in Half Year FY24 Revenue, EPS Up 6.6% MT
Correction: --EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Billion; Underlying EPS of AU$0.795 MT
EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Million; Underlying EPS of AU$0.795 MT
EBOS Group Limited Announces Interim Dividend of the Year Ending June 30, 2024, Payable 22 March 2024 CI
New Zealand shares post biggest weekly jump since Nov; Australia closed RE
New Zealand shares snap 4-day rally but set for weekly gain; Australia closed RE
New Zealand Shares Rise on Tuesday on Upbeat Economic Data; EBOS Raises Ownership in Transmedic to 90% MT
EBOS Group Raises Transmedic Stake to 90% from 51% MT
EBOS Group Limited acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million. CI
Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk CI
EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit CI
NZ's EBOS not to proceed with $2.44 billion Greencross acquisition RE
NZ's EBOS not to proceed with acquisition in animal care segment RE
Chart EBOS Group Limited
More charts
EBOS Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care, and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services, and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. It sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
32.66 NZD
Average target price
38.37 NZD
Spread / Average Target
+17.47%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. EBO Stock
  4. News EBOS Group Limited
  5. New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO